Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 18/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 18/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922370 | 0.76 | PRKCQ (0.39) | CYP11B1CYP11B2PRKCQ | |
| SCHEMBL14809369 | 0.75 | CYP11B2 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL12844265 | 0.72 | LRRK2 (0.39) | — | |
| SCHEMBL21718414 | 0.72 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL18125583 | 0.71 | CYP11B2 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL12533909 | 0.71 | AOC1 (0.32) | — | |
| SCHEMBL1215960 | 0.71 | CYP11B2 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL14822356 | 0.71 | CYP11B2 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL5336784 | 0.69 | PRKCQ (0.54) | CYP11B1CYP11B2PRKCQ | |
| SCHEMBL23619884 | 0.68 | RPS6KA3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2099796-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | CYP11B1 691/4885CYP11B2 925/4885PRKCQ 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.